References for: association

Full identifier: http://purl.org/np/RA5I80bakV6K-AUQuFwaNohFxsuBpuCJR8g_e1vzs3vgs#association

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:01:14.488Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:01:14.488Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:01:14.488Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:01:14.488Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:01:14.488Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:01:14.488Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-30T07:01:14.488Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
bendamustine hydrochloride injection is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia cll efficacy relative to first line therapies other than chlorambucil has not been established 1 1 indolent b cell non hodgkin lymphoma nhl that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen 1 2 bendamustine hydrochloride injection is indicated for the treatment of patients with chronic lymphocytic leukemia efficacy relative to first line therapies other than chlorambucil has not been established bendamustine hydrochloride injection is indicated for the treatment of patients with indolent b cell non hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen
Leoni Bücken
2021-06-30T07:01:14.488Z